HU217439B - Tetrazolil-epesav-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Tetrazolil-epesav-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények Download PDFInfo
- Publication number
- HU217439B HU217439B HU9401443A HU9401443A HU217439B HU 217439 B HU217439 B HU 217439B HU 9401443 A HU9401443 A HU 9401443A HU 9401443 A HU9401443 A HU 9401443A HU 217439 B HU217439 B HU 217439B
- Authority
- HU
- Hungary
- Prior art keywords
- formula
- group
- bile acid
- hydrogen
- compound
- Prior art date
Links
- 0 CC(CCC(N)=O)C(CC1)[C@@](C)([C@@](*)C2)C1(C)[C@@]1[C@]2[C@@](C)(CC[C@@](*)C2)[C@]2C[C@]1* Chemical compound CC(CCC(N)=O)C(CC1)[C@@](C)([C@@](*)C2)C1(C)[C@@]1[C@]2[C@@](C)(CC[C@@](*)C2)[C@]2C[C@]1* 0.000 description 2
- RQZZNEXGHJQFJH-RGULEQPZSA-N CC(CCC(N)=O)C(CC[C@H]1[C@@H]([C@H](C2)[C@@](C)(CC[C@H](C3)O)[C@@H]3C3)[C@@]3(C)O)[C@@]1(C)[C@H]2O Chemical compound CC(CCC(N)=O)C(CC[C@H]1[C@@H]([C@H](C2)[C@@](C)(CC[C@H](C3)O)[C@@H]3C3)[C@@]3(C)O)[C@@]1(C)[C@H]2O RQZZNEXGHJQFJH-RGULEQPZSA-N 0.000 description 1
- IJFXHKFVRJVZLS-BOKCDFKGSA-N CC(CCC(Nc1n[nH]nn1)=O)C(CC1)[C@@](C)(CC[C@@H]2[C@@](C)(CC[C@H](C)C3)[C@@H]3C3)[C@H]1[C@@H]2[C@@]3(C)O Chemical compound CC(CCC(Nc1n[nH]nn1)=O)C(CC1)[C@@](C)(CC[C@@H]2[C@@](C)(CC[C@H](C)C3)[C@@H]3C3)[C@H]1[C@@H]2[C@@]3(C)O IJFXHKFVRJVZLS-BOKCDFKGSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4315368 | 1993-05-08 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HU9401443D0 HU9401443D0 (en) | 1994-08-29 |
| HUT67390A HUT67390A (en) | 1995-04-28 |
| HU217439B true HU217439B (hu) | 2000-01-28 |
Family
ID=6487579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9401443A HU217439B (hu) | 1993-05-08 | 1994-05-06 | Tetrazolil-epesav-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5466815A (enExample) |
| EP (1) | EP0624596B1 (enExample) |
| JP (1) | JP3476157B2 (enExample) |
| KR (1) | KR100333149B1 (enExample) |
| AT (1) | ATE163938T1 (enExample) |
| AU (1) | AU666440B2 (enExample) |
| CA (1) | CA2123048C (enExample) |
| CY (1) | CY2119B1 (enExample) |
| CZ (1) | CZ289515B6 (enExample) |
| DE (1) | DE59405410D1 (enExample) |
| DK (1) | DK0624596T3 (enExample) |
| ES (1) | ES2115096T3 (enExample) |
| FI (1) | FI942075L (enExample) |
| GR (1) | GR3026496T3 (enExample) |
| HU (1) | HU217439B (enExample) |
| IL (1) | IL109581A (enExample) |
| NO (1) | NO304795B1 (enExample) |
| NZ (1) | NZ260469A (enExample) |
| TW (1) | TW289757B (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0624593A3 (de) * | 1993-05-08 | 1995-06-07 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel. |
| TW289020B (enExample) * | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
| US6323190B1 (en) | 1998-07-31 | 2001-11-27 | The Univeristy Of Georgia Research Foundation, Inc. | Estrogen mimetics lacking reproductive tract effects |
| MXPA01011070A (es) | 1999-04-30 | 2003-06-30 | Arch Dev Corp | Derivados de esteroides. |
| US7086134B2 (en) * | 2000-08-07 | 2006-08-08 | Shipley Company, L.L.C. | Alignment apparatus and method for aligning stacked devices |
| CN1498222A (zh) * | 2001-02-08 | 2004-05-19 | 芝加哥大学 | 类固醇衍生物 |
| US20070197484A1 (en) * | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| US7078396B2 (en) * | 2001-05-03 | 2006-07-18 | Arch Development Corporation | Method of treating disorder related to high cholesterol concentration |
| DK1392713T3 (da) * | 2001-05-03 | 2008-02-18 | Univ Chicago | Lever-X-receptoragonister |
| US6816317B2 (en) * | 2002-01-31 | 2004-11-09 | Lightel Technologies Inc. | Collimator for ready fitting to an optical device with precise optical alignment without need for adjusting positions or angles to compensate for offsets or deviations during optical device assembly and method of making same |
| EP1494533A2 (en) * | 2002-04-12 | 2005-01-12 | The University of Chicago | Farnesoid x-activated receptor agonists |
| WO2006005667A2 (en) * | 2004-07-08 | 2006-01-19 | Novo Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
| US20070032464A1 (en) * | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| US7960439B1 (en) | 2006-06-12 | 2011-06-14 | Iowa State University Research Foundation, Inc. | Environmentally sensitive foldable oligomers |
| US8829213B2 (en) * | 2009-07-29 | 2014-09-09 | The University Of Chicago | Liver X receptor agonists |
| EP3400944B1 (en) | 2010-11-04 | 2020-07-15 | Albireo AB | Ibat inhibitors for the treatment of liver diseases |
| AU2011326872C1 (en) | 2010-11-08 | 2015-02-19 | Albireo Ab | A pharmaceutical combination comprising an IBAT inhibitor and a bile acid binder |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| JP6751020B2 (ja) | 2014-06-25 | 2020-09-02 | Ｅａファーマ株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| CA2966885A1 (en) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| KR20170099909A (ko) | 2014-11-26 | 2017-09-01 | 이난타 파마슈티칼스, 인코포레이티드 | Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법 |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| HK1245100A1 (zh) * | 2015-02-11 | 2018-08-24 | Enanta Pharmaceuticals, Inc. | 作为fxr/tgr5激动剂的胆汁酸类似物及其使用方法 |
| NZ735126A (en) | 2015-03-31 | 2022-10-28 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| EP3290429A1 (en) * | 2015-04-28 | 2018-03-07 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Cholic acid derivative, and preparation method and medical use thereof |
| CA3011619C (en) | 2016-02-09 | 2024-01-02 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| RU2750944C2 (ru) | 2016-02-09 | 2021-07-06 | Альбирео Аб | Пероральный состав холестирамина и его применение |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
| US10323061B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
| AU2017368069B2 (en) | 2016-11-29 | 2021-07-08 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
| WO2018152171A1 (en) | 2017-02-14 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr agonists and methods of use thereof |
| JP7136802B2 (ja) | 2017-04-07 | 2022-09-13 | エナンタ ファーマシューティカルズ インコーポレイテッド | スルホニルカルバマート胆汁酸誘導体の調製のためのプロセス |
| CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
| JP7328207B2 (ja) | 2017-08-09 | 2023-08-16 | アルビレオ・アクチボラグ | コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用 |
| TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| SG11202012170PA (en) | 2018-06-20 | 2021-01-28 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| KR20210116523A (ko) * | 2019-01-14 | 2021-09-27 | 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 | 테트라졸론 치환된 스테로이드 및 이의 용도 |
| EP3921027B1 (en) | 2019-02-06 | 2023-07-19 | Albireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| EP3921028B1 (en) | 2019-02-06 | 2022-11-09 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| EP4379384A3 (en) * | 2019-03-19 | 2024-08-28 | Siemens Healthcare Diagnostics Inc. | Compositions, devices, and methods of mitigating lipoprotein interference in in vitro diagnostic assays for hydrophobic analytes |
| AR120682A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar |
| PE20230234A1 (es) | 2019-12-04 | 2023-02-07 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar |
| CN114761018B (zh) | 2019-12-04 | 2025-12-02 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| JP7696898B2 (ja) | 2019-12-04 | 2025-06-23 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| TWI871392B (zh) | 2019-12-04 | 2025-02-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| TWI865673B (zh) | 2019-12-04 | 2024-12-11 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AR120674A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiazepina y su uso como ácido biliar |
| WO2021110884A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP7748451B2 (ja) | 2020-08-03 | 2025-10-02 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| EP4243831A1 (en) | 2020-11-12 | 2023-09-20 | Albireo AB | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| CA3198216A1 (en) | 2020-12-04 | 2022-06-09 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| CN119053330A (zh) | 2022-04-22 | 2024-11-29 | 阿尔比里奥公司 | 皮下给药asbt抑制剂 |
| JP2025519406A (ja) * | 2022-06-09 | 2025-06-26 | シャンドン ルイ ファーマシューティカル カンパニー リミテッド | １９－ノルｃ３，３－二置換ｃ２１－アザシクロ置換ステロイド及びその使用方法 |
| WO2023237728A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
| CA3259103A1 (en) | 2022-07-05 | 2024-01-11 | Albireo Ab | Benzothia (di)azepine compounds and their use as bile acid modulators |
| EP4629997A1 (en) | 2022-12-09 | 2025-10-15 | Albireo AB | Asbt inhibitors in the treatment of renal diseases |
| WO2025119319A1 (zh) * | 2023-12-08 | 2025-06-12 | 山东绿叶制药有限公司 | 一种gabaa受体调节剂的晶型及其制备方法和应用 |
| WO2025146507A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2025146508A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3930696A1 (de) * | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
| US5250524A (en) * | 1990-12-06 | 1993-10-05 | Hoechst Aktiengesellschaft | Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals |
-
1993
- 1993-11-23 TW TW082109825A patent/TW289757B/zh active
-
1994
- 1994-05-02 DE DE59405410T patent/DE59405410D1/de not_active Expired - Lifetime
- 1994-05-02 DK DK94106848T patent/DK0624596T3/da active
- 1994-05-02 AT AT94106848T patent/ATE163938T1/de not_active IP Right Cessation
- 1994-05-02 EP EP94106848A patent/EP0624596B1/de not_active Expired - Lifetime
- 1994-05-02 ES ES94106848T patent/ES2115096T3/es not_active Expired - Lifetime
- 1994-05-05 FI FI942075A patent/FI942075L/fi unknown
- 1994-05-05 US US08/238,741 patent/US5466815A/en not_active Expired - Lifetime
- 1994-05-06 NO NO934800A patent/NO304795B1/no not_active IP Right Cessation
- 1994-05-06 CA CA002123048A patent/CA2123048C/en not_active Expired - Fee Related
- 1994-05-06 NZ NZ260469A patent/NZ260469A/en unknown
- 1994-05-06 AU AU61947/94A patent/AU666440B2/en not_active Ceased
- 1994-05-06 CZ CZ19941135A patent/CZ289515B6/cs not_active IP Right Cessation
- 1994-05-06 JP JP09442494A patent/JP3476157B2/ja not_active Expired - Fee Related
- 1994-05-06 HU HU9401443A patent/HU217439B/hu not_active IP Right Cessation
- 1994-05-06 IL IL109581A patent/IL109581A/en not_active IP Right Cessation
- 1994-05-07 KR KR1019940009971A patent/KR100333149B1/ko not_active Expired - Fee Related
-
1998
- 1998-04-03 GR GR980400679T patent/GR3026496T3/el unknown
- 1998-09-29 CY CY9800037A patent/CY2119B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06329695A (ja) | 1994-11-29 |
| FI942075A7 (fi) | 1994-11-09 |
| AU6194794A (en) | 1994-11-10 |
| EP0624596A3 (de) | 1995-06-07 |
| NO941677D0 (no) | 1994-05-06 |
| GR3026496T3 (en) | 1998-07-31 |
| CA2123048A1 (en) | 1994-11-09 |
| FI942075L (fi) | 1994-11-09 |
| CZ113594A3 (en) | 1994-12-15 |
| US5466815A (en) | 1995-11-14 |
| EP0624596B1 (de) | 1998-03-11 |
| HU9401443D0 (en) | 1994-08-29 |
| AU666440B2 (en) | 1996-02-08 |
| ATE163938T1 (de) | 1998-03-15 |
| CA2123048C (en) | 2005-11-29 |
| CY2119B1 (en) | 2002-04-26 |
| IL109581A0 (en) | 1994-08-26 |
| ES2115096T3 (es) | 1998-06-16 |
| HUT67390A (en) | 1995-04-28 |
| TW289757B (enExample) | 1996-11-01 |
| CZ289515B6 (cs) | 2002-02-13 |
| IL109581A (en) | 1998-03-10 |
| NZ260469A (en) | 1995-03-28 |
| NO304795B1 (no) | 1999-02-15 |
| JP3476157B2 (ja) | 2003-12-10 |
| DK0624596T3 (da) | 1998-10-07 |
| DE59405410D1 (de) | 1998-04-16 |
| FI942075A0 (fi) | 1994-05-05 |
| EP0624596A2 (de) | 1994-11-17 |
| NO941677L (no) | 1994-11-09 |
| KR100333149B1 (ko) | 2002-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU217439B (hu) | Tetrazolil-epesav-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HU217446B (hu) | Norepesav-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| JP3424978B2 (ja) | 単量体胆汁酸誘導体、その調製方法およびそれを含有する低脂血剤 | |
| HUT67522A (en) | Bile acid derivatives, process for producing them and pharmaceutical compositions containing them | |
| JP2642090B2 (ja) | 胆汁酸誘導体 | |
| KR100319562B1 (ko) | 담즙산유도체,이의제조방법및이를함유하는저지질혈증제 | |
| JP3237882B2 (ja) | 胆汁酸誘導体、その製法および医薬としてのこれらの化合物の使用 | |
| AU757366B2 (en) | Propanolamine derivatives linked with bile acid used for treating disorders of the lipid metabolism | |
| Miki et al. | Sulfonate analogues of chenodeoxycholic acid: metabolism of sodium 3 alpha, 7 alpha-dihydroxy-25-homo-5 beta-cholane-25-sulfonate and sodium 3 alpha, 7 alpha-dihydroxy-24-nor-5 beta-cholane-23-sulfonate in the hamster. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HMM4 | Cancellation of final prot. due to non-payment of fee |